Akiram Therapeutics, AKIR001, Lutetium-177, Radiopharmaceuticals, Molecular Radiotherapy, Phase 1 Clinical Trial, CD44v6, Targeted Cancer Therapy, Precision Oncology, Radioimmunotherapy

Uppsala, Sweden, October 13, 2026 Akiram Therapeutics, a Swedish clinical-stage biotechnology company specializing in targeted molecular radiotherapy, has announced...